STAT-Dx QIAGEN
Edit

STAT-Dx QIAGEN

https://www.stat-dx.com/
Last activity: 16.07.2019
Probably Closed
Categories: CareDevelopmentDiagnosticsFastGrowthHardwareManufacturingMarketPlatformProduct
STAT-Dx (Barcelona, Spain) focuses on the development of diagnostic solutions where fast and accurate diagnostic results are needed. Patients which based on symptoms enter the critical care setting (emergency room or intensive care unit) need fast and accurate diagnosis for clinical decision making. The DiagCORE in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device. State-of-the-art sample preparation, microfluidic and detection technologies are integrated into one system. The system can be used in both the point-of-care and central laboratory.
Since Gilde invested in STAT-Dx, the Spanish company accelerated the growth of its organization, built in-house manufacturing capabilities, expanded its product pipeline, obtained European market approval for two diagnostic tests and prepared go-to-market activities. STAT-Dx was acquired by QIAGEN in 2018.
Mentions
2
Location: Spain, Catalonia, Barcelona

Investors 1

Mentions in press and media 2

DateTitleDescription
16.07.2019Life Sciences and Gaming Startups Bloom in BarcelonaBarcelona has some of the most fascinating architecture in the world, with landmarks like La Sagrada Familia, Casa Batlló, and Parc Güell. This inspiring setting is also one of the largest entrepreneurial hubs in Southern Europe with local ...
01.02.2018Qiagen compra Stat-Dx por $191M. Desinvierten Ysios, CaixaCR, Axis, Kurma, Siemens, Idinvest, Gilde y Boehringer01/02/2018 Nota de prensa QIAGEN COMPRA STAT-DX POR $191 MILLONES. DESINVIERTEN YSIOS, CAIXACR, AXIS, KURMA, SIEMENS, IDINVEST, GILDE Y BOEHRINGER. La entidad de capital riesgo (venture capital) Ysios Capital, ha anunciado hoy el acuerdo...

Reviews 0

Sign up to leave a review

Sign up Log In